The IRBM peptide chemistry team is proud to announce a new publication in ACS Medicinal Chemistry Letters in collaboration with the outstanding drug discovery team at Merck & Co. (Kenilworth, NJ).
Discovery of 4-((1-(1H-imidazol-2-yl)alkoxy)methyl)pyridines as a new class of Trypanosoma cruzi growth inhibitors
Stopping the night time kissing bug: IRBM’s scientists recently published a Bioorganic & medicinal chemistry paper on a novel class of inhibitors for Chagas Disease, an infectious disease caused by the parasite Trypanosoma cruzi, spread by an insect commonly referred to as the ‘kissing bug’, so called as they often bite people on the thin skin around the eyes or mouth, usually while the person is asleep. Chagas disease affects over 8 million people, mostly in Latin America, but increasingly in Texas too, and this new class of Trypanosoma cruzi growth inhibitors has the potential to make a difference to a lot of people.